Effectiveness of HIV pre-exposure prophylaxis in Peru

October 9, 2012

In this week's PLOS Medicine, Anna Borquez from Imperial College London and an international group of authors developed a mathematical model representing the HIV epidemic among men who have sex with men (MSM) and transwomen in Lima, Peru as a test-case for the effectiveness of HIV pre-exposure prophylaxis (PrEP).

The model was used to investigate the population-level impact, cost, and cost-effectiveness of PrEP under a range of different scenarios.

The authors found that strategic PrEP intervention could be a cost-effective addition to existing HIV prevention strategies for MSM populations.

However, despite being cost-effective, a substantial expenditure would be required to generate significant reductions in incidence of HIV.

Explore further: Hope for more options in couples where one partner is HIV positive

More information: Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, et al. (2012) The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study. PLoS Med 9(10): e1001323. doi:10.1371/journal.pmed.1001323

Related Stories

Hope for more options in couples where one partner is HIV positive

November 15, 2011
In sub-Saharan Africa, couples in long-term relationships where one partner is HIV-positive and the other is HIV-negative (HIV serodiscordant couples) could benefit from anti-AIDS drugs (antiretroviral therapy) given either ...

HIV racial disparities noted for men who have sex with men

July 20, 2012
(HealthDay) -- Similar racial disparities are seen in HIV infection for men who have sex with men (MSM) in the United States and the United Kingdom, according to a study published online July 20 in The Lancet.

Drugs used to treat HIV also reduce risk of HIV infection

July 10, 2012
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers ...

Giving preventive drug to men at high risk for HIV would be cost-effective, study shows

April 16, 2012
A once-a-day pill to help prevent HIV infection could significantly reduce the spread of AIDS, but only makes economic sense if used in select, high-risk groups, Stanford University researchers conclude in a new study.

Recommended for you

Study suggests a way to stop HIV in its tracks

December 1, 2017
When HIV-1 infects an immune cell, the virus travels to the nucleus so quickly there's not enough time to set off the cell's alarm system.

Discovery puts the brakes on HIV's ability to infect

November 30, 2017
Viewed with a microscope, the virus faintly resembles a pineapple—the universal symbol of welcome. But HIV, the virus that causes AIDS, is anything but that. It has claimed the lives of more than 35 million people so far.

Rising levels of HIV drug resistance

November 30, 2017
HIV drug resistance is approaching and exceeding 10% in people living with HIV who are about to initiate or reinitiate first-line antiretroviral therapy, according to the largest meta-analysis to date on HIV drug resistance, ...

Male circumcision and antiviral drugs appear to sharply reduce HIV infection rate

November 29, 2017
A steep drop in the local incidence of new HIV infections accompanied the rollout of a U.S.-funded anti-HIV program in a large East-African population, according to a study led by researchers at Johns Hopkins Bloomberg School ...

Combination HIV prevention reduces new infections by 42 percent in Ugandan district

November 29, 2017
A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections ...

Research on HIV viral load urges updates to WHO therapy guidelines

November 24, 2017
A large cohort study in South Africa has revealed that that low-level viraemia (LLV) in HIV-positive patients who are receiving antiretroviral treatment (ART) is an important risk factor for treatment failure.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.